Xenon Pharmaceuticals (NASDAQ:XENE) Posts Earnings Results, Meets Estimates

Xenon Pharmaceuticals (NASDAQ:XENE) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.17), Zacks reports. During the same period in the previous year, the firm posted ($0.83) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Xenon’s Phase III X-TOLE2 for azetukalner (AZK) exceeded expectations with strong efficacy and tolerability, and the company plans an NDA submission in Q3 2026 with an anticipated U.S. launch in late 2027/early 2028 (standard FDA review + DEA scheduling).
• Long-term open-label data are compelling — ≥48-month patients showed a 91% median reduction in monthly focal seizures and ~40% were seizure-free for ≥12 months, supporting AZK’s potential differentiation and durable benefit.
• Xenon is expanding AZK’s opportunity beyond focal epilepsy — EXACT (primary generalized tonic‑clonic seizures) is enrolling and three Phase III depression studies (X‑NOVA 2 readout expected H1 2027) could materially broaden the addressable market if successful.
• Early-stage pain programs XEN1701 (NaV1.7) and XEN1120 (KV7) are completing first‑in‑human studies this year with plans to advance to Phase II acute pain POC trials, but these are early-stage and carry typical development risk.
• Financially strong after a $747.5M offering, Xenon ended Q1 with about $1.3 billion in cash and equivalents, which management says funds operations into 2029 and supports launch and pipeline advancement.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock traded down $2.59 during midday trading on Thursday, reaching $56.00. 576,359 shares of the company were exchanged, compared to its average volume of 917,107. The firm’s 50-day simple moving average is $54.64 and its 200-day simple moving average is $46.62. Xenon Pharmaceuticals has a 1 year low of $28.19 and a 1 year high of $63.95. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -12.84 and a beta of 0.65.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XENE. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Guggenheim reiterated a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research report on Monday, March 9th. Needham & Company LLC lifted their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Finally, HC Wainwright lifted their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $73.13.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 7,308 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. This trade represents a 26.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrea Difabio sold 1,342 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider directly owned 7,301 shares in the company, valued at approximately $403,234.23. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 296,707 shares of company stock valued at $17,845,365. Insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XENE. Goldman Sachs Group Inc. boosted its stake in Xenon Pharmaceuticals by 7.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after buying an additional 32,486 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $532,000. Sei Investments Co. acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $711,000. The Manufacturers Life Insurance Company acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $816,000. Finally, Alliancebernstein L.P. lifted its stake in shares of Xenon Pharmaceuticals by 14.2% in the 2nd quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.